

OVERVIEW

- Developing novel therapeutics and diagnostics for infectious diseases, medical countermeasures and substance abuse
- Advancing use of Bucillamine for COVID-19 and companion long COVID diagnostic, and nerve agent exposure
- Clinical study with psilocybin for substance use disorder
- Robust patent portfolio (*16 patents and patent applications*)
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases Long COVID	Phase 2	IND filing for clinical study
Bucillamine	Medical Countermeasures Nerve Agent	Pre-clinical	Defence R&D Canada – Research funded by Suffield Research Centre, Canadian Department of National Defence
Diagnostic Rapid Test	LONG COVID	Pre-commercial prototype	Preparing submission for FDA approval pathway
Oral Psilocybin <i>(Oral Capsule)</i>	Substance Use Disorder Methamphetamine	Phase 1/2	Preparing end-of-Phase 2 meeting with FDA

STRATEGIC PARTNERS



EXPECTED MILESTONES H1-2024

- ▶ Complete reformulation of Bucillamine IV for future studies in infectious diseases and rare disorders
- ▶ FDA meeting for Long COVID Lab and Rapid Test diagnostic development
- ▶ FDA meeting for Bucillamine to treat Long COVID
- ▶ Results of Bucillamine for nerve agent exposure at DRDC
- ▶ Interim results for Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin

TEAM

Management

Michael Frank, Chairman & CEO
Carmelo Marrelli, CFO
Derrick Welch, Advisor

Scientific and Clinical

Dr. Kelly McKee, Dr. Arshi Kizilbash, M.D., Dr. Osnesmo Mpanju, Regulatory Affairs, Dr. Douglas Fraser, Scientist

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Sovenna and Andrew Lindzon

CONTACT INFORMATION

Revive Therapeutics Ltd.
82 Richmond Street East
Toronto, ON M5C 1P1

Tel: 1-888-901-0036
E-mail: info@revivethera.com
Website: revivethera.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
Share Price:	\$0.025 (May 16, 2024)
52-week High / Low:	CAD \$0.08 / \$0.02
Shares Outstanding:	418,564,269 common shares 35,320,334 stock options 63,317,263 warrants (\$0.05 - \$0.20)
Market Cap:	CAD ~ 10,500,000